Novel therapeutic strategies for rare mutations in non-small cell lung cancer
Authors:
Open Access
- 5 May 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-21
Abstract
Lung cancer is still the leading cause of cancer-related mortality. Over the past two decades, the management of non-small cell lung cancer (NSCLC) has undergone a significant revolution. Since the first identification of activating mutations in the epidermal growth factor receptor (EGFR) gene in 2004, several genetic aberrations, such as anaplastic lymphoma kinase rearrangements (ALK), neurotrophic tropomyosin receptor kinase (NTRK) and hepatocyte growth factor receptor (MET), have been found. With the development of gene sequencing technology, the development of targeted drugs for rare mutations, such as multikinase inhibitors, has provided new strategies for treating lung cancer patients with rare mutations. Patients who harbor this type of oncologic driver might acquire a greater survival benefit from the use of targeted therapy than from the use of chemotherapy and immunotherapy. To date, more new agents and regimens can achieve satisfactory results in patients with NSCLC. In this review, we focus on recent advances and highlight the new approval of molecular targeted therapy for NSCLC patients with rare oncologic drivers.Keywords
Funding Information
- Sichuan University Education Foundation (2022SCUH0032)
- Chongqing Science and health joint medical research project (2021MSXM318)
This publication has 192 references indexed in Scilit:
- Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung CancerJAMA Oncology, 2021
- Savolitinib: First ApprovalDrugs, 2021
- Amivantamab: First ApprovalDrugs, 2021
- A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid TumorsThe Oncologist, 2021
- Tepotinib: First ApprovalDrugs, 2020
- New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)Current Oncology Reports, 2020
- Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer modelsInternational Journal of Cancer, 2019
- TRK Inhibition: A New Tumor-Agnostic Treatment StrategyTargeted Oncology, 2018
- MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skippingInvestigational New Drugs, 2017
- ROS receptor tyrosine kinase: a new potential target for anticancer drugsMedicinal Research Reviews, 2010